Clinical bottom line
Emerging therapies targeting immune metabolism represent a promising frontier in autoimmune disease management, aiming to modulate dysregulated immune cell metabolic pathways that contribute to chronic inflammation and autoimmunity. Current evidence, largely from preclinical and early-phase clinical studies, suggests potential efficacy and acceptable safety profiles for agents such as tyrosine kinase 2 (TYK2) inhibitors and spleen tyrosine kinase (Syk) inhibitors. However, robust clinical trial data remain limited, and the heterogeneity of autoimmune diseases necessitates cautious interpretation. Clinicians should consider these therapies as investigational and monitor ongoing trials to inform future practice.
What the evidence shows
Immune metabolism influences immune cell activation, differentiation, and effector functions, with metabolic reprogramming implicated in autoimmune pathogenesis. Targeting metabolic enzymes and signaling pathways offers a novel mechanism to restore immune tolerance.
Recent reviews highlight the therapeutic potential of TYK2 inhibitors, which modulate cytokine signaling critical in autoimmune inflammation. Rzeczycki et al. (2025) summarize emerging data showing TYK2 inhibitors reduce disease activity in conditions such as psoriasis and systemic lupus erythematosus, with favorable safety profiles in early-phase trials. Similarly, Heidari et al. (2025) provide a comprehensive review of Syk and Bruton's tyrosine kinase (BTK) inhibitors in immune thrombocytopenia (ITP), demonstrating promising efficacy in refractory cases and manageable adverse events.
Beyond kinase inhibitors, Municio et al. (2021) discuss therapies targeting trained immunity and metabolic rewiring in innate immune cells, which may have broader implications across autoimmune diseases by attenuating chronic inflammatory responses.
While chimeric antigen receptor (CAR)-based cellular therapies primarily target immune cell populations, Wong et al. (2026) note that metabolic modulation may enhance CAR-T cell persistence and function, suggesting combinatorial approaches could optimize outcomes.
Caveats and uncertainty
The current evidence base is largely derived from early-phase clinical trials, preclinical models, and mechanistic studies, limiting generalizability to routine clinical practice. Autoimmune diseases are heterogeneous, and metabolic pathways may differ across conditions and patient subsets, complicating uniform therapeutic application.
Long-term safety data are sparse, particularly regarding off-target metabolic effects and potential immunosuppression risks. The complexity of immune metabolism also raises concerns about unintended consequences on host defense and tissue homeostasis.
Furthermore, biomarkers to predict response to metabolic therapies are not well established, hindering patient selection and personalized treatment strategies.
How this may change practice
As evidence matures, therapies targeting immune metabolism could complement or provide alternatives to existing immunomodulatory agents, especially for patients with refractory or relapsing autoimmune diseases. Clinicians should stay informed about ongoing phase 2 and 3 trials to evaluate efficacy and safety outcomes.
Integration of metabolic modulators may also enable combination regimens that enhance therapeutic efficacy while minimizing toxicity. However, until robust clinical data and guidelines emerge, these therapies remain investigational and should be considered within clinical trial settings or specialized centers.
Future practice may also incorporate metabolic biomarkers to guide therapy selection and monitor treatment response, advancing precision immunology.